Q4 2025 CorMedix Inc Earnings Call Transcript
Key Points
- Cormedix Inc (CRMD) achieved peak sales of just under $260 million in 2025, highlighting strong revenue performance.
- The acquisition of Mota Therapeutics was successfully closed and integrated, achieving a target synergy of $35 million.
- The company is affirming its 2026 financial guidance with expected revenue of $300 to $320 million and adjusted EBITDA of $100 to $125 million.
- Cormedix Inc (CRMD) completed its first analyst R&D day, receiving positive feedback from thought leaders on market opportunities for its antifungal product, Rozeo.
- The company ended the quarter with strong liquidity, having cash and cash equivalents of $148.5 million, driven by robust operating cash flow.
- The transition of TDAPA reimbursement for DefenCAF to a bundled add-on mechanism may lead to price erosion in the latter half of 2026.
- Operating expenses increased significantly to $48.2 million in Q4 2025, reflecting the expanded cost structure post-acquisition.
- The company's guidance for 2027 does not include potential upside from new customers or managed care contracting, indicating uncertainty in future growth projections.
- Enrollment for the NutriGard clinical study is only 30% complete, potentially delaying study completion to early 2027.
- The legislative environment remains uncertain, affecting the timing and potential retroactivity of the TDAPA extension bills.
Good morning and welcome to the Corps medics 4th quarter and full year 2025 earnings and corporate update conference call. Today's conference call is being recorded. There will be a question-and-answer session at the end of today's presentation, and instructions on how to ask a question will be given at that time.
At this time, I would like to turn the conference call over to Dan Ferry from Life Sy Advisors. Please go ahead.
Good morning.
And welcome to the Corps medics 4th quarter and full year 2025 earnings and corporate update conference call.
Leading the call today is Joe Teddico, Chairman and Chief Executive Officer of Corpsmedics, and he is joined by Liz Hurlbert, EVP and Chief Operating Officer.
And Susan Blum, EVP and Chief Financial Officer.
In addition, Beth Zellner Hoffman, EVP and Chief Legal and Compliance Officer, Mike Seckler, EVP and Chief Commercial Officer, and Dr. Matt David, EVP and Chief Physics Officer, are also on the line and will be available
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
